The drugmaker's approved treatment, Kisunla (donanemab), works by binding to deposited amyloid plaque in the brain. Its phase 3 Alzheimer's asset, remternetug, also binds to amyloid plaques. It is ...

By Dr. Priyom Bose, Ph.D. Scientists unveil a novel supramolecular therapy that shields human neurons from amyloid-induced ...